Skip to content
PreclinicalResearch compoundLimited evidence

Tabernanthalog

Experimental, non-hallucinogenic ibogaine derivative that showed antidepressant-like effects in rodents; not studied in humans.

NootropicPsychoplastogenPsychoplastogenNeuroprotectionSerotoninBDNFnoo.affects.neuroplasticity

Pharmacology

ClassPsychoplastogen · Neuroprotection
Primary target5-HT2A receptor partial agonism (biased toward plasticity)
Targets3 receptor targets
Half-lifeNot characterized in humans; short-acting in rodent models
OnsetNo human data (rodent studies use single or repeated dosing)
EvidenceLimited evidence
Affected systemsSerotoninBDNFnoo.affects.neuroplasticity

Contents

DETAILED OVERVIEW

What is Tabernanthalog?

Tabernanthalog (TBG) is an experimental compound: a lab-designed, non-hallucinogenic version of ibogaine, the psychoactive substance of the iboga plant. It is meant to boost the brain's ability to adapt, meaning the rebuilding of connections between nerve cells. It is not approved as a medicine anywhere and is not a dietary supplement; it is only a research compound, and its legal situation is unclear.

It switches on one of the serotonin receptors, but in a way that starts a nerve-growth pathway instead of hallucinations. In rodents, antidepressant-like effects, less alcohol- and drug-seeking behavior and repair of stress-damaged neural circuits were seen. It has never been tested in humans, so its safety is unknown. It was designed to avoid ibogaine's dangerous heart-rhythm problem (QT prolongation), but this has not been confirmed in people. Its safety in pregnancy and breastfeeding has not been established, and in theory it is risky in heart disease and alongside drugs that act on the serotonin system.

Mechanism

Partial serotonin 2A receptor activator; boosts nerve adaptability

Evidence

Preclinical only (cell + rodent, no human data)

Legal status

Unapproved research compound

Receptor profile

  • 5-HT2A receptorStrong
  • TrkB / BDNF signalingModerate
  • hERG channel (low affinity, reduced cardiac-rhythm risk)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • No human safety data: only cell and animal (rodent) studies exist; the compound has never been tested in humans
  • Unknown long-term safety and incomplete toxicity profile in humans
  • As a 5-HT2A agonist it may theoretically cause transient anxiety, blood-pressure rise or headache
  • Designed to reduce the cardiac-rhythm (hERG/QT) risk seen with ibogaine, but this is unconfirmed in humans
  • Nicotinic (α7, α9α10) receptor inhibition from animal data: human relevance unknown

Contraindications · 4

  • Pregnancy and breastfeeding: safety not established, avoid
  • Cardiovascular disease, arrhythmia or prolonged QT: caution due to 5-HT2A/hERG activity
  • Serotonergic drugs (SSRIs, MAO inhibitors, triptans): theoretical serotonin-syndrome risk
  • Not an approved medicine or dietary supplement; experimental research compound, not recommended without clinical supervision

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Tabernanthalog is a lab-designed compound built from the psychoactive ingredient of the iboga plant (ibogaine), engineered to skip the hallucinogenic effects. In animal studies it eased depression-like symptoms, reduced alcohol- and drug-seeking behavior, and helped restore stress-damaged neural connections. It is still purely an experimental compound with essentially no human data yet.

Telegram

Have a question about Tabernanthalog?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC14H18N2O
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.